News & Events News SalubrisBio parent company Salubris Pharmaceuticals announces IND approval of JK07 Phase I study in China September 21, 2020 SalubrisBio parent company Salubris Pharmaceuticals announces $265M investment from the Carlyle Group to further innovative R&D September 1, 2020 SalubrisBio announces IND approval by FDA of JK07 Phase I study in the US February 24, 2020 SalubrisBio parent company Salubris Pharmaceuticals announces partnership with JT Pharmaceuticals (Tokyo, Japan) to commercialize HIF-PH inhibitor enarodustat for the treatment of renal anemia in China: December 25, 2019 SalubrisBio parent company Salubris Pharmaceuticals announces investment of $10M in Viracta Therapeutics (San Diego, USA) to support development of their kick-and-kill combination cancer therapy December 4, 2018 SalubrisBio parent company Salubris Pharmaceuticals announces investment of $20M in MedAlliance SA (Nyon, Switzerland) to support development of their novel sirolimus-coated balloon for coronary and peripheral vascular diseases May 22, 2018 SalubrisBio parent company Salubris Pharmaceuticals announces investment of $8M in Mercator Medsystems (Emeryville, USA) to support development of their novel microinjection platform technology June 21, 2018 SalubrisBio parent company Salubris Pharmaceuticals announces investment of $5M in GO Therapeutics (Cambridge, USA) to support development of their novel microinjection platform technology June 21, 2018 Upcoming Events Please check back soon for future events
